Now that autumn is here, we decided it’s time to take a look back at the trends in the UK pharma and labs sector, and highlight the latest developments.
Despite the rapidly changing landscape and outlook, capex activity remains strong. This has primarily been driven in 2020/2021 by drug development and discovery in the COVID era.
The booming R&D activity and the ever-growing viral vector segment are fueling many of the investments and our database currently contains:
Here are some of the main players:
Our research team has compiled the full UK pharma and labs sector outlook packed with insights on the trends and projects to look out for. Access to this report and all the projects it refers to is reserved to our pharma & labs subscribers.
To discuss our subscription options, book a call with one of our team.